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ABSTRACT
Antibody gene transfer presents an appealing alternative to conventional 
antibody protein therapy. This pre-clinical study evaluates the impact of various 
parameters on the pharmacokinetics and efficacy of in vivo expressed DNA-based 
anti-HER2 monoclonal antibodies (mAbs), newly engineered and delivered via 
intramuscular electrotransfer in mice. Plasma concentrations of trastuzumab and 
4D5, its murine IgG1 equivalent, peaked on average between 1–15 µg/ml, depending 
on the administration and configuration of the encoding plasmid DNA (pDNA). A dual 
expression cassette system outperformed a single 2A-based cassette, and the CAG 
promoter was superior to a muscle-specific ΔUSE-based promoter. A ‘gene therapy-
compatible’ Gene Transport Unit (gtGTU, FIT Biotech), a plasmid backbone that 
co-encodes viral elements, failed to improve in vivo reporter and mAb expression 
compared to a conventional plasmid. In BALB/c mice, trastuzumab detection was lost 
within two weeks after pDNA administration due to anti-drug antibodies. This host 
immune response was addressed by expressing trastuzumab in immune-compromised 
mice, or by gene transfer of murine 4D5 in BALB/c mice. Both approaches maintained 
single-digit µg/ml mAb concentrations for at least six to nine months, and allowed to 
boost mAb expression over time by pDNA re-dosing. In a breast cancer mouse model, 
prophylactic and therapeutic DNA-based trastuzumab or 4D5 led to complete tumor 
regressions, thereby rivalling with the administration of milligrams of mAb protein. 
In conclusion, our study demonstrates proof of concept for antibody gene transfer 
in cancer, provides critical insights in the engineering and application of DNA-based 
antibodies, and serves to advance this modality in oncology and beyond.
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INTRODUCTION
Recombinant monoclonal antibodies (mAbs) are one 
of today’s most successful therapeutic classes in oncology. 
A wider accessibility and implementation, however, is 
hampered by the high production cost and prolonged 
need for frequent administration. The surge in more 
effective but costly mAb combination therapies further 
adds to the financial burden. These issues highlight the 
need for innovations in conventional mAb production and 
administration.
In vivo antibody gene transfer seeks to administer 
the mAb-encoding nucleotide sequence, rather than the 
mAb protein. This allows the site of administration, e.g. 
the muscle, to produce the therapeutic in a cost- and labor-
effective manner for a prolonged period of time. Applied 
expression platforms, mostly in a pre-clinical setting, 
include viral vectors, plasmid DNA (pDNA), and, more 
recently, mRNA [1]. Each of these expression platforms 
comes with a set of challenges. Our vehicle of interest, 
pDNA, generally gives a lower transgene expression 
than viral vectors, but presents less concerns in terms of 
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immunogenicity, biosafety and payload capacity. Compared 
to pDNA, mRNA typically leads to a more rapid and higher 
expression, but for a shorter duration of time [1].
Only few studies have evaluated DNA-mediated 
antibody gene transfer in cancer [1], and it is uncertain 
whether sufficiently high and prolonged systemic titers can 
be attained to e.g. impact solid tumors. Different approaches 
are available to anticipate these concerns. The inefficient in 
vivo transfection of pDNA can be dramatically improved 
by electroporation, a methodology that has shown to be 
safe and tolerable for pre-clinical and clinical application 
[2, 3]. Other factors specifically relate to enhanced 
construct engineering, and include the choice of promoter, 
expression cassette configuration, and plasmid backbone – 
all underexplored in the context of antibody gene transfer.
The current pre-clinical study aims to build proof of 
concept for intramuscular antibody gene electrotransfer 
in oncology, and evaluate the impact of several relevant 
parameters on the pharmacokinetics (PK) and efficacy 
of DNA-based antibodies. Initial assessment of pDNA 
electrotransfer and design was done using a novel triple-
reporter construct. The anti-HER2 trastuzumab served as 
a model for antibody gene transfer, as it presents a well-
characterized and effective mAb in the field of oncology 
[4] for which a murine equivalent, i.e. 4D5 [5], and 
clinical reference material are available.
RESULTS
In vivo validation of a triple-reporter plasmid
We established a triple-reporter expression 
cassette, in which a CAG promoter drives the 
expression of Gaussia luciferase (Gluc), enhanced 
green fluorescent protein (eGFP) and firefly luciferase 
2 (fluc) (CAG-GEF), each separated from one another 
using a self-cleaving foot-and-mouth-disease virus 
(FMDV) 2A peptide [6]. Gluc, a 20-kDa protein, is 
secreted extracellularly, while eGFP and fluc remain 
intracellularly. eGFP allows for microscopic and 
histological analyses, while Gluc and fluc are detected 
via bioluminescent imaging of plasma and mice, 
respectively. The expression cassette was cloned into 
a ‘gene therapy-compatible’ Gene Transport Unit 
(gtGTU), a plasmid backbone developed by FIT Biotech 
(Finland) that co-encodes the nuclear anchoring E2 
protein and harbors multimeric E2 binding sites (pCAG-
GEF-gtGTU, Figure 1A) [7, 8]. After verifying in vitro 
expression (data not shown), in vivo functionality was 
evaluated via intramuscular electrotransfer in BALB/c 
mice (n = 7). The applied electroporation protocol 
consisted of three series of four 20 ms square-wave 
pulses of 120 V/cm with a 50 ms interval between 
the pulses and polarity switching after two of the 
four pulses. One day post pDNA administration, 
all three reporters were detected (Figure 2A), 
with plasma Gluc and muscle fluc being highly 
correlated (r = 0.86, P < 0.05). Whole-mice bio-
luminescent imaging confirmed that fluc expression 
was restricted to the electroporated muscle site (data 
not shown). Given the less quantitative nature of 
eGFP, this readout was not included in current and 
subsequent analyses. These findings demonstrated that 
pCAG-GEF-gtGTU is functional in vivo, and allows for 
simultaneous detection of both localized and secreted 
reporters. 
Figure 1: Schematic reporter- or antibody-encoding plasmid configurations. Abbreviations; BS: E2 binding sites, eGFP: 
enhanced green fluorescent protein, fcs: furin cleavage site, fluc: firefly luciferase, Gluc: Gaussia luciferase, gtGTU: gene therapy-
compatible Gene Transport Unit, HC: heavy chain, LC: light chain, pA: poly A, RSV LTR: Rous sarcoma virus 5′ long terminal repeat 
promoter.
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Impact of electrical field strength and 
hyaluronidase pretreatment 
In addition to the above applied electroporation 
protocol, two additional field strengths (80 V/cm and 160 V/
cm) were evaluated in BALB/c mice, while maintaining the 
other pulse parameters. Muscle fluc, one day after pCAG-
GEF-gtGTU electrotransfer, served as readout (Figure 2B). 
A field strength of 80 V/cm did not increase fluc expression 
compared to no electroporation (P = 0.986), unlike 120 V/
cm and 160 V/cm (P < 0.005). Increasing the field strength 
from 120 to 160 V/cm failed to further improve fluc (P = 
0.994). These observations were maintained throughout 
a three-week follow-up (data not shown). Increasing the 
number of pulse series from three to six did not impact 
fluc expression. Injecting the muscle with 40 µl of 0.4 U/
µl hyaluronidase, an enzyme that degrades hyaluronic acid 
and increases tissue permeability, prior to electroporation 
enhanced fluc expression by 3.2-fold (P < 0.05) (Figure 
2B). Increasing the dose of hyaluronidase from 0.4 to 
4 U/µl did not increase fluc (data not shown). Following 
these results, the three series of 120 V/cm pulses were 
maintained in subsequent experiments, unless stated 
otherwise. The use of hyaluronidase was restricted to the 
antibody gene transfer work.
Added value of a muscle-specific promoter for 
reporter gene transfer
Using plasma Gluc and muscle fluc as readouts, 
the ubiquitous CAG promoter was compared with a 
muscle-specific promoter in BALB/c mice. The latter is 
based on three copies of a modified UpStream Enhancer 
(ΔUSE) of the human slow troponin I gene, linked to 
the gene’s minimal promoter [9] (pΔUSE-GEF-gtGTU, 
Figure 1A). Following intramuscular electrotransfer of 
equimolar pDNA amounts, CAG outperformed ΔUSE 
in the first seven to ten days for both reporters (Figure 
2C–2D). Plasma Gluc was not detected beyond two 
weeks (Figure 2D), whereas muscle fluc expression 
remained detectable for at least six weeks. During 
follow-up, CAG fluc did decrease more pronounced than 
ΔUSE fluc, with the latter outperforming CAG beyond 
day 14 (Figure 2C). These data hinted that a muscle-
specific promoter could lead to a more stable prolonged 
transgene expression.
Figure 2: Intramuscular reporter gene transfer in BALB/c mice. (A) Expression of enhanced green fluorescent protein (eGFP), 
Gaussia luciferase (Gluc) and firefly luciferase (fluc) one day after intramuscular (i.m.) pCAG-GEF-gtGTU electrotransfer. (B) Impact of 
applied electrical field and hyaluronidase (hyal) pretreatment on muscle fluc expression one day after i.m. pCAG-GEF-gtGTU. *P < 0.05, 
**P < 0.005. (C–D) Intramuscular fluc (C) and plasma Gluc (D) resulting from the CAG promoter and the muscle-specific ΔUSE promoter. 
*P < 0.05, **P < 0.005. Abbreviations; gtGTU: gene therapy-compatible Gene Transport Unit, n.s.: not significant, p/s: photons per second, 
RLU: relative light unit, UV: ultraviolet.
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Added value of the gtGTU for reporter gene 
transfer
To assess its benefit, gtGTU was compared to a 
conventional plasmid, identical in design except for the 
presence of the co-encoded viral elements (pCAG-GEF, 
Figure 1B). Intramuscular electrotransfer of 45 µg pCAG-
GEF-gtGTU and equimolar amounts of pCAG-GEF 
in BALB/c mice showed a highly similar muscle fluc 
during the 14-week follow-up (Figure 3A). Similarly, no 
differences in plasma Gluc were observed in the first week 
following pDNA electrotransfer, before the signal was lost 
(Figure 3B). Both constructs were subsequently compared 
at 100-fold lower doses. Plasma Gluc resulting from 
these low pDNA amounts was not detectable. A dose-
response between administered pDNA and muscle fluc 
was obvious. No difference in fluc expression was present 
between both plasmids in the first two weeks. Similar as 
observed with the 100-fold higher dosing, gtGTU fluc 
decreased three weeks after pDNA electrotransfer (Figure 
3C). In contrast, fluc from the conventional plasmid 
remained stable for a longer period of time. The reason 
for the more rapid decrease in gtGTU fluc could be linked 
to a more pronounced immune response, but is beyond 
the scope of the current study. Due to poor performance, 
gtGTU use was discontinued in the remaining reporter 
experiments. 
Reporter gene transfer in immune-compromised 
mice
To assess the impact of the host immune system on 
reporter expression, fluc and Gluc expression following 
pCAG-GEF intramuscular electrotransfer were evaluated 
in immune-compromised athymic nude and RAG2−/−γc−/− 
mice. Although the resulting reporter expressions varied 
somewhat between each strain, muscle fluc and plasma 
Gluc remained highly stable throughout the 16–17 weeks 
of follow-up (Figure 3D–3E). These data indicated that the 
decrease of reporter expression in BALB/c mice (Figure 
3A) is linked to an immune response against the expressed 
reporters. 
Figure 3: Added value of the gtGTU plasmid for reporter gene transfer. (A–C) Muscle firefly luciferase (fluc) (A and C) and 
plasma Gaussia luciferase (Gluc) (B) in BALB/c mice following intramuscular (i.m.) electrotransfer of equimolar amounts of pCAG-GEF-
gtGTU or conventional control pCAG-GEF. *P < 0.05. Plasma Gluc is displayed one and seven days after pDNA electrotransfer. (D–E) 
Muscle fluc (D) and plasma Gluc (E) in athymic nude and RAG2−/−γc−/− mice. Abbreviations; p/s: photons per second, RLU: relative light 
unit.
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Pharmacokinetics of DNA-based trastuzumab in 
BALB/c mice
The impact of different variables on the PK of in 
vivo expressed trastuzumab was evaluated in BALB/c 
mice. First, two novel mAb cassette configurations 
were engineered. With gtGTU still under evaluation for 
reporter gene transfer at that time, this plasmid backbone 
was initially used. In pCAG-tras2A-gtGTU, mAb 
expression was driven by a single CAG promoter, with 
the trastuzumab heavy chain (HC) and light chain (LC) 
separated by a RKRR furin cleavage site and FMDV 2A 
peptide (Figure 1C) [10, 11]. In pCAG-tras-gtGTU, a dual 
cassette approach is applied, in which each mAb chain 
is incorporated into an identical CAG-driven cassette 
(Figure 1D). When comparing both configurations, the 
dual cassette outperformed the single cassette (2.3-fold 
difference at day 7, P < 0.05). Second, in agreement with 
the reporter findings, hyaluronidase injection of the muscle 
prior to electroporation led to an increased mAb expression 
(2-fold difference at day 7, P < 0.05) (Figure 4A). Based 
on these findings, the dual cassette configuration and 
hyaluronidase pretreatment was used in all ensuing 
experiments. Third, the earlier observed dose-response for 
reporter pDNA was also obvious for trastuzumab, enabling 
higher mAb titers via increased doses or targeting multiple 
muscle sites (Figure 4B). These data demonstrated 
that plasma trastuzumab expression peaks at µg/ml 
concentrations, but is lost within two weeks after pDNA 
electrotransfer, irrespective of the applied variables.
Antibody immune response against in vivo 
expressed trastuzumab
The loss of trastuzumab in BALB/c mice was 
found to correlate with the emergence of anti-trastuzumab 
antibodies in all mice, as early as 10 days after pCAG-
tras-gtGTU electrotransfer (Figure 4C). Administration 
of an additional identical pDNA dose, one month after 
the first injection, failed to result in any detectable 
trastuzumab, but rather appeared to increase anti-drug 
antibody (ADA) titers. Presented data were collected 
using a drug-sensitive ADA assay, and confirmed with a 
drug-tolerant assay (data not shown). i.v. injection of 0.2 
mg/kg trastuzumab protein (Herceptin, Roche) in naïve 
BALB/c mice resulted in similar peak levels compared to 
DNA-based delivery, but overall gave a different picture. 
The injected trastuzumab remained detectable in plasma 
for five weeks after injection. An additional i.v. 0.2 mg/
kg trastuzumab dose in four out of eight mice, 10 days 
after the first injection, gave a PK profile highly similar 
to the first administration (Figure 4D). Anti-trastuzumab 
antibodies were only detected five weeks after the first i.v. 
injection in half of the mice (not linked to the number of 
received i.v. injections) (Supplementary Figure 1A). These 
findings indicated that ADAs are a critical hurdle to attain 
prolonged mAb expression, and that DNA-based delivery 
expedites this immune response compared to conventional 
protein administration.
Pharmacokinetics of DNA-based trastuzumab in 
immune-compromised mice
To address the ADA response, trastuzumab gene 
transfer was evaluated in athymic nude mice. In the 
meantime, it had become clear that gtGTU provided no 
benefit for in vivo reporter expression. We therefore 
compared pCAG-tras-gtGTU with conventional pCAG-
tras, identical in design except for the E2 gene cassette and 
E2 binding sites (Figure 1E). At different equimolar pDNA 
doses, gtGTU failed to show a benefit in trastuzumab 
expression compared to the conventional plasmid (Figure 
5A–5B). For both constructs, plasma trastuzumab peaked 
two to three weeks post pDNA electrotransfer, and 
remained detectable for several months. Follow-up of 
the gtGTU group was discontinued 14 weeks post pDNA 
administration. The conventional pDNA group continued 
to be monitored for 22 weeks, with plasma trastuzumab 
maintaining up to single-digit µg/ml concentrations. 
Given the lack of benefit, gtGTU use was discontinued 
in favor of a conventional plasmid in all ensuing 
experiments. Intramuscular electrotransfer of pCAG-tras 
in RAG2−/−γc−/− mice, a more immune-compromised 
strain, demonstrated a similar trastuzumab PK as in nude 
mice, both in terms of amount and duration of expression 
(Figure 5C). As expected, no anti-trastuzumab antibodies 
were detected. These data demonstrated that in vivo 
expression of trastuzumab can be maintained for several 
months in the absence of a competent host immune system. 
Pharmacokinetics of DNA-based 4D5 in BALB/c 
mice
We subsequently focused on achieving prolonged 
mAb production in immune-competent BALB/c mice, 
a more clinically relevant context. This was pursued 
by gene electrotransfer of 4D5, the murine equivalent 
of humanized trastuzumab [5]. 4D5 cDNA sequences 
were cloned into the dual CAG cassette configuration 
and conventional plasmid that was used for trastuzumab 
(pCAG-4D5, Figure 1E). Besides sequence origin, the 
impact of additional construct engineering and pDNA re-
dosing on 4D5 PK was assessed. Swapping the order of the 
HC and LC cassettes (pCAG-4D5-HCLC versus pCAG-
4D5-LCHC) demonstrated no difference throughout 
follow-up. Both constructs enabled high plasma 4D5 titers, 
peaking after three weeks at approximately 10 µg/ml, and 
maintained single-digit µg/ml concentrations for at least 
nine months (Figure 6A). Given the lack of difference, the 
original HC LC cassette order (Figure 1E) was maintained 
in subsequent experiments. Throughout follow-up, no anti-
4D5 antibodies were detected using either a drug-sensitive 
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Figure 5: Added value of the gtGTU plasmid for trastuzumab gene transfer in immune-compromised mice. (A–B) 
Plasma trastuzumab concentrations resulting from intramuscular (i.m.) electrotransfer of equimolar amounts of pCAG-tras-gtGTU and 
conventional pCAG-tras in athymic nude mice. (C) Plasma trastuzumab concentrations following i.m. electrotransfer of pCAG-tras in 
RAG2−/−γc−/− mice.
Figure 4: Trastuzumab gene transfer and trastuzumab protein administration in BALB/c mice. (A) Impact of hyaluronidase 
(hyal) pretreatment and administered construct configuration (pCAG-tras-gtGTU, a dual antibody cassette system, vs. pCAG-tras2A-gtGTU, 
a single 2A-driven antibody expression cassette) on expressed plasma trastuzumab concentrations (*P < 0.05). (B) Dose-response between 
administered pCAG-tras-gtGTU and expressed plasma trastuzumab concentrations. 150 µg pDNA was equally divided across two tibialis 
anterior muscles. 15 µg and 75 µg were injected in one tibialis anterior muscle (***P < 0.001, ****P < 0.0001). (C) Anti-trastuzumab antibodies 
start emerging 10 days after intramuscular (i.m.) electrotransfer of 75 µg pCAG-tras-gtGTU. A second pCAG-tras-gtGTU dose was given 
32 days after the first. Presented optical densities (OD) result from 50-fold diluted plasma samples after background subtraction. The figure 
insert shows the same samples, diluted 25-fold to highlight anti-trastuzumab antibodies in the first two weeks. Data are presented as mean 
± standard error of mean. (D) Plasma trastuzumab titers resulting from one or two intravenous (i.v.) injections of 0.2 mg/kg trastuzumab. 
The first plasma sample post injection was collected after one hour. The arrow indicates the timing of the second i.v. trastuzumab injection. 
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or a drug-tolerant ADA assay. Accordingly, a second 
pCAG-4D5 electrotransfer in the non-transfected tibialis 
anterior of BALB/c mice, eight weeks after the initial 
dose, resulted in a boost in 4D5 plasma concentrations 
(Figure 6B). Throughout an eight-week follow-up, CAG 
enabled five- to six-fold higher 4D5 concentrations 
compared to the muscle-specific ΔUSE promoter (Figure 
6C). This is different from the fluc data (Figure 2C), 
which could be linked to the absence of immune response 
against 4D5. As a consequence, the CAG construct was 
maintained in all subsequent experiments. In contrast to 
DNA-mediated 4D5 delivery, the PK profile of a single 
i.v. injection of 5 µg of purified 4D5 in BALB/c mice 
showed rapid loss of the circulating mAb, with only 
marginal concentrations remaining three weeks after 
injection (Figure 6D). These findings illustrated the impact 
of construct configurations on mAb titers, with species-
matched mAb sequences enabling prolonged in vivo 
expression in immune-competent animals. 
Characterization of in vitro expressed 
trastuzumab and 4D5 
In vitro expressed and purified trastuzumab and 
4D5 demonstrated the expected molecular weight on 
SDS-PAGE under non-reducing and reducing conditions. 
‘In-house’ generated trastuzumab was highly similar to 
clinical-grade trastuzumab (Herceptin, Roche) (Figure 7). 
The biological activity of these mAbs was evaluated in a 
five-day proliferation assay of BT474, a HER2+ human 
breast cancer cell line. In accordance with the literature 
[5], 4D5 (IC50 = 169.1 ng/ml + 8.7 ng/ml, mean + SEM, 
n = 6) was more active than trastuzumab (IC50 = 224.4 
ng/ml + 22.1 ng/ml, mean + SEM, n = 6, P < 0.05). In-
house trastuzumab displayed a similar activity to clinical-
grade trastuzumab (IC50 = 231.9 + 11.4 ng/ml, n = 6, P = 
0.77). These results confirmed that the engineered pCAG-
4D5 and pCAG-tras constructs express functional and 
biologically active anti-HER2 mAbs. 
Figure 6: 4D5 gene transfer and 4D5 protein administration in BALB/c mice. (A) Plasma 4D5 concentrations following a 
single intramuscular (i.m.) electrotransfer of pCAG-4D5-HCLC (heavy chain – light chain order) and pCAG-4D5-LCHC (light chain 
– high chain order). (B) Impact of repeated electrotransfer of 60 µg pCAG-4D5 on plasma 4D5 concentrations. The arrow indicates 
the timing of the second pCAG-4D5 dose. (C) Plasma 4D5 concentrations resulting from i.m. electrotransfer of equimolar amounts of 
pCAG-4D5 and muscle-specific p∆USE-4D5. ***P < 0.001, ****P < 0.0001. (D) Plasma 4D5 pharmacokinetics of a single intravenous (i.v.) 
injection of 5 µg purified 4D5. The first plasma sample post injection was collected after one hour.
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Efficacy of DNA-based trastuzumab and 4D5 in 
a breast cancer model
The in vivo efficacy of anti-HER2 mAb gene 
electrotransfer was evaluated in a BT474 breast cancer 
mouse model, either as a prophylactic or therapeutic. 
In the prophylactic setting, intramuscular pDNA 
electrotransfer was performed one week prior to 
subcutaneous tumor cell injection in athymic nude mice. 
To achieve higher mAb titers, the tibialis anterior and 
gastrocnemius were injected with 60 µg pDNA each. For 
one group of mice, this was the only treatment (‘single 
pDNA’). Another group of mice received a second 
identical pDNA dose two weeks later (‘double pDNA’), 
i.e. one week after BT474 cell injection. Prophylactic 
intramuscular pCAG-tras electrotransfer had a significant 
impact on tumor growth compared to buffer (D-PBS) or 
pNull (a plasmid without transgene expression cassette) 
(P < 0.001) (Figure 8A). After 12 weeks of follow-up, 
five complete tumor responses were observed: two out of 
ten in the single pCAG-tras group and three out of ten 
in the double pCAG-tras group. The additional pCAG-
tras dose increased plasma trastuzumab concentrations 
(Supplementary Figure 1B), but failed to improve anti-
tumor response. Among all mice that received pCAG-
tras (n = 20), higher plasma trastuzumab did correspond 
to better anti-tumor responses, as exemplified by the 
negative correlation between plasma titer and tumor 
volume five weeks after tumor cell injection (r = -0.64, 
P < 0.005). This apparent contradiction is likely related 
to the variability in attained trastuzumab concentrations 
among both groups. Prophylactic pCAG-4D5 gave very 
similar findings, with single and double pDNA dosing 
demonstrating a significant and comparable anti-BT474 
response (Figure 8B). The therapeutic setting focused on 
pCAG-tras. Based on the outcome of the prophylactic 
experiments, two modifications were made. First, to 
maximize mAb titers, mice received the four pDNA doses 
at once, rather than spread across two weeks, thereby 
targeting both legs with a total of 240 µg pCAG-tras. 
Second, the applied field strength was increased from 120 
V/cm to 160 V/cm. Athymic nude mice typically have a 
larger muscle mass than BALB/c mice, which can lead to a 
higher tissue impedance and lower transfection efficiency, 
warranting adapted pulses. To assess how DNA-based 
mAb delivery compared to the conventional mAb protein 
administration, two groups of mice received a single i.p. 
dose of either 1 or 100 mg/kg clinical-grade trastuzumab 
protein. Treatment was initiated three days after BT474 
cell injection when tumors were palpable. pCAG-tras had 
a significant impact on tumor growth, outperforming both 
buffer and 1 mg/kg trastuzumab (P < 0.001 from week 2 
on). No significant difference was observed with 100 mg/
kg trastuzumab (P between 0.12–0.70 from day 17 on). 
1 mg/kg trastuzumab had no significant effect on tumor 
growth (Figure 8C). After 12 weeks of follow-up, pCAG-
tras enabled stable disease in three out of ten, complete 
tumor response in three out of ten, and a lesion below 1 
mm3 in one mouse. 1 mg/kg trastuzumab led to a complete 
tumor regression in one animal and no stable diseases. 
100 mg/kg induced complete responses in eight out of ten, 
and a lesion below 1 mm3 in one mouse. Individual tumor 
volumes for each group are plotted in Supplementary 
Figure 1C. Anti-tumor responses were reflected in the 
survival curves of each group, using a tumor volume 
threshold of 1000 mm3. pCAG-tras outperformed buffer 
(P < 0.0001) and 1 mg/kg trastuzumab (P < 0.01) 
and showed no significant difference with 100 mg/
Figure 7: Trastuzumab and 4D5 SDS-PAGE profile. Coommasie blue-stained gel following SDS-PAGE of 2.5 µg of in-house 
expressed and purified trastuzumab (‘T’), clinical-grade trastuzumab (‘H’, Herceptin, Roche) and in-house expressed and purified 4D5 
(‘4D5’) under non-reducing and reducing conditions.
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kg trastuzumab (P = 0.146) (Figure 8D). The different 
trastuzumab plasma concentrations among treatment 
groups again illustrated the difference between DNA- and 
protein-based mAb administration (Figure 8E). After two 
weeks, trastuzumab was mostly cleared in the 1 mg/kg 
group, while expressed trastuzumab in the pCAG-tras 
group reached an average of 17 µg/ml – still significantly 
below the 160 µg/ml of the 100 mg/kg group. After six 
weeks, trastuzumab concentrations of pCAG-tras group 
were similar to those of the 100 mg/kg group (Figure 8E). 
Overall, no weight loss or other obvious signs of treatment 
toxicity were observed in any of the tumor experiments. 
Therapeutic pCAG-tras led to better anti-tumor responses 
than the prophylactic application. This is likely because 
of the higher trastuzumab concentrations in the former 
setting, which are associated with higher pDNA dosing 
and adjusted field strength. Overall, these results 
demonstrated that antibody gene electrotransfer enables 
therapeutically effective mAb titers, and can rival with the 
administration of milligrams of trastuzumab protein.
Figure 8: Efficacy and pharmacokinetics of DNA-based anti-HER2 antibodies in a mouse breast cancer model. 
(A) Anti-tumor responses of prophylactic trastuzumab gene transfer in a BT474 breast cancer model in athymic nude mice. One week prior 
to subcutaneous (s.c.) injection of BT474 cells, mice received an intramuscular (i.m.) electrotransfer of buffer (D-PBS), pNull (an empty 
plasmid), or a 2 × 60 µg pCAG-tras dose (‘single pTras’ group). Half of the latter mice received an additional 2 × 60 µg pCAG-tras dose 
two weeks later, one week after s.c. tumor cell injection (‘double pTras’ group). Stars indicate the statistical difference between the pNull 
and single pTras group (*P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001). (B) Anti-tumor responses of prophylactic 4D5 gene transfer 
in a BT474 breast cancer model. Experimental setup is identical to panel A, except no pNull group is included. Stars indicate the statistical 
difference between the buffer and single p4D5 group (*P < 0.05, **P < 0.005, ***P < 0.001). (C) Anti-tumor responses of therapeutic 
trastuzumab gene transfer in a BT474 breast cancer model in athymic nude mice. Three days after s.c. injection of BT474 cells, mice 
received an i.m. electrotransfer of buffer (D-PBS), electrotransfer of four intramuscular 60 µg pCAG-tras injections, or an intraperitoneal 
(i.p.) injection of either 1 mg/kg or 100 mg/kg trastuzumab protein (Herceptin, Roche). Stars indicate the statistical difference between the 
buffer and pTras group (**P < 0.005, ***P < 0.001, ****P < 0.0001). Arrows indicate the timing of the second (A–B) or first treatment (C). 
(D) Survival curves of the different treatment groups (buffer, pTras, and 1 mg/kg or 100 mg/kg i.v. trastuzumab) until 12 weeks of follow-
up, based on a 1000 mm3 tumor volume threshold. (E) Pharmacokinetic trastuzumab profile of the tumor-bearing athymic nude mice that 
received either an i.m. electrotransfer of pCAG-tras or an i.p. injection of 1 mg/kg or 100 mg/kg trastuzumab protein. Stars indicate the 
statistical difference between the pCAG-tras and 100 mg/kg trastuzumab group (**P < 0.005, ***P < 0.001). Tumor data were plotted as long 
as all groups were complete, i.e. no animals were sacrificed. Abbreviation; n.s.: not significant.
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DISCUSSION
Our study built pre-clinical proof of concept for 
antibody gene electrotransfer in oncology, and evaluated 
the impact of several underexplored parameters on the PK 
and efficacy of DNA-based trastuzumab or 4D5, including 
administration, plasmid backbone, expression cassette, 
and immunogenicity. 
For pDNA administration, a robust intramuscular 
electroporation protocol was established using the 
guidance of a newly engineered triple-reporter 
cassette. In agreement with the literature [12, 13], both 
reporter and mAb expression was further increased 
using hyaluronidase pretreatment of the muscle. This 
enzyme is currently already applied in patients [14, 
15], making it a potential adjuvant for clinical antibody 
gene electrotransfer. As plasmid backbone, we initially 
evaluated a ‘gene therapy-compatible’ version of the 
GTU, a plasmid designed by FIT Biotech and under 
clinical evaluation for HIV DNA vaccination [8]. 
gtGTU was engineered by the company to contain less 
immunostimulatory sequences than GTU (undisclosed 
data) while maintaining the mechanism of action. The 
backbone co-encodes the bovine papillomavirus type 1 
E2 nuclear anchoring protein and simultaneously harbors 
multimeric E2 binding sites. This allows the expressed 
E2 to tether the gtGTU plasmid to chromatin, reportedly 
improving transgene expression via enhanced segregation 
and partitioning. In addition, E2 has been postulated to 
act as transcriptional activator for the gene of interest 
[7, 8]. Our findings, however, refute these claims. gtGTU 
consistently failed to provide benefit for in vivo reporter 
and mAb expression, and was abandoned in favor of a 
conventional plasmid. For expression cassette design, 
different promoters and configurations were explored. 
The use of tissue-specific promoters has been suggested 
to promote prolonged stable transgene expression [16, 
17]. The muscle-specific ΔUSE previously showed a 
strength similar to potent ubiquitous promoters [9], and 
was therefore selected in the current study for evaluation. 
ΔUSE mAb expression, however, did significantly worse 
than CAG, limiting its relevance for said application. 
Using CAG, a dual mAb cassette system outperformed a 
single 2A-based cassette, despite the substantially larger 
size. The former construct subsequently emerged as our 
platform of choice for DNA-mediated antibody gene 
transfer. This was further supported by the high similarity 
between the in-house expressed trastuzumab and its 
clinical-grade counterpart. 
Overall, the reporter data contributed to the design 
of a robust mAb expression system. At the same time, 
the current study illustrated the challenges in identifying 
favorable expression parameters. Moreover, irrespective 
of plasmid administration or engineering, the humoral 
immune response, i.e. ADAs, emerged as a critical hurdle 
for successful antibody gene transfer. This is in line with 
previous findings [18], but is characterized more in depth 
in the current study. Compared to protein delivery, DNA-
based transfer clearly aggravated the ADA response. This 
observation is exploited in the field of DNA vaccines 
[19], but is not warranted for therapeutic gene transfer 
purposes. Two routes were thereto pursued: i) expressing 
trastuzumab in immune-compromised mice, and ii) gene 
transfer of the murine 4D5 IgG1 in immune-competent 
mice. 
Both approaches allowed prolonged mAb 
expression, at least six to nine months after pDNA 
administration, and boosting of mAb expression by 
pDNA re-dosing. In the absence of an antibody immune 
response, trastuzumab and 4D5 demonstrated comparable 
in vivo expression, with plasma titers ranging between 
1–15 µg/ml depending on the pDNA dose and construct 
engineering. The PK profile of expressed mAbs was in 
clear contrast to that of injected mAb protein, which, in 
accordance with the molecule’s half-life, was typically 
cleared a few weeks after administration. 
Only few reports have reported the in vivo 
expression of anti-HER2 trastuzumab or 4D5. Most 
used viral vectors, which resulted in 30 to 120 µg/ml 
mAb plasma peak concentrations in mice [1, 20, 21]. 
Albeit our attained mAb levels were lower, significant 
anti-tumor responses were achieved in a breast cancer 
mouse model, including multiple complete regressions. 
DNA-based trastuzumab thereby outperformed a 1 mg/
kg trastuzumab protein dose (≈ 20 µg), and was similar 
to 100 mg/kg trastuzumab (≈ 2 mg), a high dose in pre-
clinical settings. As a reference, about 70% of studies 
on breast cancer mouse models apply trastuzumab 
dosing below 75 mg/kg [22]. Given the clear correlation 
between circulating mAb concentrations and anti-tumor 
responses, the efficacy of antibody gene transfer is 
expected to further benefit from advances that enhance 
transgene expression. 
The generated PK and efficacy data illustrate the 
broad applicability of DNA-based antibody gene transfer. 
In pre-clinical R&D, it could serve as a straightforward 
tool to express and evaluate multiple DNA-based 
antibody leads in vivo, avoiding the laborious task of 
producing and purifying each lead. In the clinic, it could 
facilitate prophylactic, maintenance or combination 
treatments, thereby addressing the current hurdles with 
conventional mAb therapy. However, clinical translation 
of antibody gene transfer still faces several challenges 
and uncertainties, most notably biosafety (e.g. tumor and 
organ distribution, immunogenicity, and control of mAb 
expression) and efficacy (ability to attain therapeutic mAb 
titers in patients). Innovations in expression platform, 
administration and antibody technology are expected to 
address these challenges, and unlock the vast potential of 
antibody gene transfer.
In conclusion, our study provides critical insights 
in the design and application of DNA-based antibodies. 
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Guided by reporter and construct engineering studies, we 
achieved robust and prolonged in vivo expression of two 
anti-HER2 mAbs, whose efficacy rivalled with high-dose 
mAb protein administration in a breast cancer model. 
Overall, the reported findings serve to advance antibody 
gene transfer in oncology and beyond.
MATERIALS AND METHODS
Cell lines and reagents
293F Freestyle suspension cells (purchased from 
Thermo Fisher Scientific in 2015) were maintained in 
FreeStyle 293 Expression Medium on a CO2-resistant 
orbital shaker (Thermo Fisher Scientific) in a 37° C 
humidified incubator at 8% CO2. The HER2+ human 
breast cancer cell line BT474 was a kind gift from Dr. 
Christos Sotiriou (Breast Cancer Translational Research 
Laboratory J.C. Heuson, Jules Bordet Insitute, Brussels, 
Belgium) in July 2014. Cell line identity was confirmed 
using short tandem repeat analysis at the Laboratory 
of Forensic Biomedical Sciences, KU Leuven, most 
recently in October 2017. Cells were grown in RPMI 
medium, supplemented with 10% heat-inactivated fetal 
bovine serum, 1% penicillin-streptomycin, and 1 mmol/L 
sodium pyruvate (Thermo Fisher Scientific), at 37° C 
in a humidified incubator at 5% CO2. Clinical-grade 
trastuzumab (Herceptin, 150 mg vial, H4426B02 lot) was 
kindly provided by Roche (Belgium), reconstituted in 
sterile milliQ H2O according to the instructions, aliquoted 
and stored at −80° C until use.
Mice
Gene transfer and tumor experiments were 
performed in five to nine weeks old female mice with 
an approximate weight of 18–20 grams. BALB/c mice 
(BALB/cAnNCrl) were bred at the KU Leuven Animal 
Research Center or purchased at Janvier (France). Athymic 
nude mice (hsd: athymic nude-foxn1nu) were purchased at 
Envigo (The Netherlands). C57BL/6J RAG2−/−γc−/− mice 
were purchased from the division Translational Research 
in Gastrointestinal Disorders (Department of Chronic 
Diseases, Metabolism and Ageing) at KU Leuven. Plasma 
was collected via retro-orbital bleeding, processed and 
stored at −20° C until analysis. All animal experiments 
were approved by the KU Leuven Animal Ethics 
Committee (project P163/2013).
Reporter- and mAb-encoding plasmids
Reporter or mAb cDNA sequences were cloned 
into the gtGTU plasmid (developed and provided by FIT 
Biotech under research agreement) or a conventional 
plasmid. Both plasmids include an ampicillin-resistance 
gene and pUC origin of replication, and are identical 
except for the presence of the E2 gene cassette and 
multimeric E2 binding sites (Figure 1). In gtGTU, 10 
copies of the E2 binding sites are located directly upfront 
of the promoter. The E2 expression cassette, driven by 
a Rous sarcoma virus 5´ long terminal repeat promoter, 
is placed in tandem of the reporter or antibody cassette 
[7, 8]. The Kozak sequence preceded the start codon of 
each transgene followed by an appropriate signal peptide. 
cDNA sequences of the murine anti-HER2 4D5 (IgG1) 
and of humanized trastuzumab (IgG1) were derived 
from the literature [5]. Transgene sequences were codon-
optimized for mouse and synthesized by Genewiz, and 
cloned into the plasmid expression cassettes by Icosagen. 
Synthesis and cloning were verified via sequencing and 
restriction analyses. In vitro transgene expression was 
evaluated by ELISA, SDS-PAGE or Western blot (data 
not shown). pDNA was produced in E. coli, purified using 
the NucleoBond Xtra Maxi EF kit (Machery - Nagel) 
according to the manufacturer’s instructions, and eluted 
in sterile D-PBS (no magnesium, no calcium, 14190144, 
Thermo Fisher Scientific). Plasmid purity and integrity 
was assessed via spectrophotometry and agarose gel 
electrophoresis.
Intramuscular pDNA electrotransfer in mice
pDNA administration was done in the tibialis 
anterior muscle, unless stated otherwise. The site of 
delivery was prepared using depilatory product (Veet, 
Reckitt Benckiser), at least one day prior to pDNA 
injection. For antibody gene electrotransfer, muscles 
were injected with 40 µl of 0.4 U/µl hyaluronidase 
from bovine testes (H3506, Sigma, reconstituted in 
sterile saline), approximately one hour prior to pDNA 
electrotransfer. Intramuscular injection of 30 µl of pDNA, 
formulated in sterile D-PBS at the indicated amounts, was 
immediately followed by in situ electroporation using 
the NEPA21 Electroporator (Sonidel) with CUY650P5 
tweezer electrodes (Sonidel) at a fixed width of 5 mm. 
Signa Electrode Gel (Parker Laboratories) was applied to 
the muscle and electrodes to decrease tissue impedance 
below 0.4 kiloohm. Pulse delivery was verified using the 
NEPA21 readout. 
In vivo reporter imaging 
eGFP expression was visualized using a 
microscope with a fluorescent light source (Leica 
MZ10F). fluc expression was quantified by non-invasive 
bioluminescence imaging (IVIS Spectrum, Perkin Elmer) 
at the molecular imaging for Small Animals Center 
(moSAIC) at KU Leuven. Mice were sedated with 
isoflurane inhalation and subcutaneously injected with 
126 mg/kg D-luciferin substrate (Promega) at 15 mg/ml 
in sterile D-PBS (14190144, Thermo Fisher Scientific). 
Total radiance (p/s, photons per second) was collected at 
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fluc signal plateau. Gluc in plasma was analyzed using 
a FLUOstar Omega Microplate Reader (BMG Labtech) 
in black 96-well plates. Per well, 100 µl of 100 µM 
coelenterazine (Nanolight Technology, Pinetop, AZ) was 
added to 5 µl plasma via automated injection. Data was 
analyzed with MARS Software (BMG Labtech). Counts 
(RLU, relative light unit) 1 sec after injection of the 
substrate were used for analyses. Readout was corrected 
for the pretreatment plasma count. 
In vitro mAb production and purification 
Trastuzumab and 4D5 proteins were produced in 
vitro in 293F cells and purified from the supernatant. 
Transfection was done using pCAG-tras or pCAG-4D5 
with X-tremeGENE HP DNA Transfection Reagent 
(Roche) in Freestyle media (Thermo Fisher Scientific), 
following the manufacturer’s protocol. Five days after 
transfection, cells and media were collected. Supernatant 
was obtained via centrifugation and 0.2 µm filtration 
and stored at −20° C. Subsequent purification of the 
expressed mAbs was done on ÄKTAprime plus (GE 
Healthcare Life Sciences), using a 1 ml pre-packed 
column with the Protein A affinity resin Amsphere 
A3 (JSR Life Sciences) according to the manufacturer’s 
protocol. Following elution with 100 mM sodium acetate 
pH 3.5 and neutralisation with 1M Tris pH 9, fractions 
were pooled and dialysed to 20 mM sodium phosphate, 
150 mM NaCl pH 7.5, aliquoted and stored at −80° C. 
Batches of purified mAb were evaluated for consistency 
on a HER2-coated ELISA and by SDS-PAGE (under non-
reducing and 2-mercapto-ethanol reducing conditions). 
For the latter, 2.5 µg of mAb was formulated in NuPAGE 
LDS Sample Buffer, loaded on a 10-well NuPage Bis-Tris 
4–12% Protein Gel and run in NuPage MES SDS Running 
Buffer in a XCell SureLock Mini-Cell Electrophoresis 
System (Thermo Fisher Scientific), according to the 
manufacturer’s instructions. Novex Sharp Pre-stained 
Protein Standard (LC5800, Thermo Fisher Scientific) was 
used as marker. Pictures of the Coommasie blue-stained 
gel were taken with the ChemiDoc MP System (Bio-Rad) 
and processed using Image Lab Software 6.0 (Bio-Rad). 
ELISA for mAb quantification
Trastuzumab concentrations were quantified with 
a HER2-coated SHIKARI Q-TRAS ELISA (Matriks 
Biotek), according to the manufacturer’s instructions. A 
dedicated 4D5 ELISA was developed in-house. 96-well 
plates were coated overnight at 4° C with 500 ng/ml 
human HER2 (10004-H08H, Sino Biologicals) in PBS. 
Plates were blocked with 1% BSA in PBS for two hours 
at RT. Samples were diluted in PTAE (PBS 0.1% BSA, 
0.002% Tween 80, 5 mM EDTA) and incubated on the 
blocked HER2-coated plates for one hour at RT. Serial 
two-fold dilutions of purified 4D5, with concentrations 
ranging between 60 and 0.94 ng/ml, were used as 
calibration curve. Detection of the captured 4D5 was 
done with goat anti-mouse IgG – HRP (GAM/IgG/PO, 
Novo Nordisk, 1:10000 dilution in PTA) and incubated 
for one hour at RT. Each incubation step was preceded by 
a washing step with PBS 0.05% Tween 20. Plates were 
developed for 30–45 minutes using o-phenylenediamine 
and H2O2 in citrate buffer. The reaction was stopped with 
4 M H2SO4. Absorption was measured at 490 nm using 
an ELx808 Absorbance Microplate Reader (BioTek 
Instruments). Sample concentrations were calculated 
based on the 4D5 calibration curve using a non-linear 
regression fit (GraphPad Prism 7.0).
ELISA for ADA detection 
The presence of antibodies against the in vivo 
expressed mAb was assessed via a drug-sensitive bridging 
or a drug-tolerant affinity capture elution (ACE) ELISA 
setup. The bridging assay was performed as follows. 96-
well plates were coated overnight at 4° C with 1 µg/ml 
trastuzumab (Herceptin, Roche) or 500 ng/ml purified 
4D5 in PBS, and blocked with 1% BSA in PBS for two 
hours at RT. Plasma samples were diluted in PTAE and 
incubated on the blocked mAb-coated plates for one hour 
at RT. Detection of captured antibodies was done with 
biotinylated trastuzumab or 4D5 (EZ-Link Sulfo-NHS-
LC-Biotin, Thermo Fisher Scientific), respectively, at a 
concentration of 500 ng/ml in PTA, followed by 30 minutes 
incubation with streptavidin-poly HRP (M2032, Sanquin) 
1:10000 in PTA. Each incubation step was preceded by a 
washing step with PBS + 0.05% Tween 20. Plates were 
developed for 30–45 minutes using o-phenylenediamine 
and H2O2 in citrate buffer. The reaction was stopped with 
4 M H2SO4. Absorption was measured at 490 nm using 
an ELx808 Absorbance Microplate Reader (BioTek 
Instruments). The drug-tolerant ACE assay was set up as 
previously described [23].
In vitro biological activity of the expressed mAbs 
The activity of trastuzumab and 4D5, purified 
from pCAG-tras or pCAG-4D5 transfected 293F cell 
supernatants, was evaluated in a WST-8 BT474 cell 
viability assay (Cell Counting Kit, Dojindo). 10000 
BT474 cells were seeded per well in a 96-well plate, 
followed by the immediate application of serial 
dilutions of the mAbs, with concentrations ranging from 
500 to 10 ng/ml. 120 hours after mAb administration, 
WST-8 was added and incubated up to 5 hours at 37° C. 
Absorptions were measured at 450 nm using an ELx808 
Absorbance Microplate Reader (BioTek Instruments), 
and normalized between cell controls of medium and 
no-cell wells of medium. IC50 values were derived 
from a non-linear fitted sigmoidal dose-response curve 
(GraphPad Prism 7.0).
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Breast cancer mouse model 
Five to six weeks old female athymic nude mice 
were subcutaneously injected in the flank with 5 × 106 
BT474 cells in 150 µl RPMI medium (Thermo Fisher 
Scientific) at 4 mg/ml matrigel (356235, BD Biosciences). 
To assure cell growth of these estrogen-dependent 
tumor cells, mice received a subcutaneous injection of 
100 µg 17β-estradiol valerate (E1631, Sigma) in 50 µl 
arachnoid oil (Vandemoortele) starting one day before 
cell engraftment and continued weekly until experiment 
completion. Tumor volume was calculated using the 
formula: a x b2 x 0.5, with a being the tumor length and b 
the width. Measurements were done in duplicate using a 
digital caliper (5OLD).
Statistics
Statistical analyses and figure drawing were done 
using GraphPad Prism 7.0 (GraphPad Software). Data 
were presented as mean ± standard error of mean (SEM) 
and analyzed using the Student’s t-test, ANOVA and 
Tukey’s multiple comparison test, or Pearson’s correlation 
coefficient test. Survival curves were compared using 
Log-rank (Mantel-Cox) test. Two-sided P values below 
0.05 were considered significant.
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